Compare Kraft Heinz Co (KHC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Zimmer Biomet Holdings Inc — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| KHC | ZBH | |
|---|---|---|
Market Cap | $26.66B | $16.95B |
Volume | 31,300,109 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $103.98 |
52-Week Low | $21.21 | $79.58 |
Typical Hold Time | 129 Days | 89 Days |
Enterprise Value | $42.98B | $24.02B |
Dividend Yield | 7.12% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.48, up 2.27% today, but remains in a bearish technical trend. The company reported a net loss of $5.85 billion in 2025 due to a significant impairment charge, though recent quarters have beaten EPS estimates. Operating cash flow remains strong at $4.46 billion, supporting a $0.40 dividend. News highlights focus on brand revitalization efforts, such as new Philadelphia cream cheese flavors, as part of a broader turnaround strategy.
The outlook is mixed: valuation metrics like P/B of 0.74 suggest potential undervaluation, but persistent net losses and high debt pose risks. Analyst sentiment is cautious with a consensus price target of $24.50. The stock's near-term direction hinges on successful execution of cost management and volume recovery initiatives amid competitive pressures.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
